Deep Small RNA Sequencing of BRAF V600E Mutated Papillary Thyroid Carcinoma With Lymph Node Metastasis

Yusof, Azliana Mohamad; Jamal, Rahman; Saidin, Sazuita; Muhammad, Rohaizak; Suhaimi, Shahrun Niza Abdullah; Rose, Isa Mohamed; Nazarie, Wan Fahmi Wan Mohamad; Fu, Francis Tieng Yew; Mutalib, Nurul Syakima Ab

doi:10.3389/fgene.2019.00941

Cited by 1 publication

(2 citation statements)

References 54 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Several studies have applied NGS on PTCs (3,9,26,27). The Cancer Genome Atlas (TCGA) Network described the genomic characterization of 496 PTCs, and generated data using whole genome sequencing.…”

Section: Discussionmentioning

confidence: 99%

“…Although overall prognosis of PTC is good and the mortality is stable at the rate of approximately 0.5 deaths per 100,000 (5,6), clinical evidence has shown the performances of PTC patients are quite different (3,7). On average, 50% of the patients are presented with lymph node metastases (LNM) at diagnosis, and in some cases, patients with micro papillary thyroid carcinoma could have macronodular lung metastasis (8,9).…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Exploring Somatic Alteration Associating With Aggressive Behaviors of Papillary Thyroid Carcinomas by Targeted Sequencing

Gao

Cai³

et al. 2021

Front. Oncol.

View full text Add to dashboard Cite

Wisely differentiating high-risk papillary thyroid carcinoma (PTC) patients from low-risk PTC patients preoperatively is necessary when comes to making a personalized treatment plan. It is not easy to stratify the risk of patients according to sonography or lab results before surgery. This study aims to seek out potential mutation gene markers that may be helpful in stratifying the risk of PTC. A custom panel of 439 PTC relevant and classic tumor metabolic pathway relevant genes was designed. Targeted capture sequencing was performed on 35 pairs of samples from 35 PTC tumors and 35 para-tumor thyroid tissues obtained during surgery. Variant calling and detection of cancer gene mutations were identified by bio-information analysis. Ingenuity Pathway Analysis (IPA) was performed to do functional enrichment analysis of high-frequency mutant genes. Immunohistochemistry (IHC) was performed on 6 PTC patients to explore the expression of protein associated with interested genes. Event-free survival (EFS) was calculated to determine which genes might affect the prognosis of patients. We have identified 32 high-frequency mutant genes in PTC including BRAF. RBL2 was found to be significantly correlated to event-free survival, FOXO1, MUC6, PCDHB9, NOTCH1, FIZ1, and RTN1 were significantly associated with EFS, while BRAF mutant was not correlated to any of the prognosis indicators. Our findings in this study might open more choices when designing thyroid gene panels used in FNA samples to diagnose PTC and predict the potentially aggressive behavior of PTC.

show abstract

Section: Discussionmentioning

confidence: 99%